RKDA - Arcadia Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.94
+0.39 (+7.03%)
As of 2:05PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close5.55
Open5.58
Bid5.90 x 800
Ask5.93 x 900
Day's Range5.58 - 6.32
52 Week Range1.82 - 10.40
Volume1,445,324
Avg. Volume2,341,014
Market Cap37.228M
Beta (3Y Monthly)-2.52
PE Ratio (TTM)N/A
EPS (TTM)-0.94
Earnings DateAug 14, 2019 - Aug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • CNW Group

    Vapen MJ Reports 43% Revenue Increase, 23% Increase in Net Income, for Second Quarter of 2019

    Vapen MJ Reports 43% Revenue Increase, 23% Increase in Net Income, for Second Quarter of 2019

  • Thomson Reuters StreetEvents

    Edited Transcript of RKDA earnings conference call or presentation 14-Aug-19 8:30pm GMT

    Q2 2019 Arcadia Biosciences Inc Earnings Call

  • Benzinga

    Another Case For Consistent Trading

    Warrior Trading is a content partner of Benzinga. This post did not go through the Benzinga Newsdesk. Well, it took a half a month of struggles, but this Thursday marks the first time in August that I’ve ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 15, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Pivotal Software (NYSE: PVTL ) shares were ...

  • Arcadia Biosciences Announces Second-Quarter and First-Half 2019 Financial Results and Business Highlights
    PR Newswire

    Arcadia Biosciences Announces Second-Quarter and First-Half 2019 Financial Results and Business Highlights

    Company launches Archipelago™ Ventures, a strategic joint venture for superior hemp production and extraction in Hawaii DAVIS, Calif. , Aug. 14, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc.  (Nasdaq: ...

  • MarketWatch

    Arcadia Biosciences' stock up on heavy volume again, but pulls way back from earlier peak

    Shares of Arcadia Biosciences Inc. rose in active trading again on Tuesday, but pulled back sharply from an earlier peak, as the rocket ride of the past two sessions appears ready for a pause. The stock's gains have come after the food ingredients and nutritional oils company's joint venture with Biocerese Crop Solutions Corp. , Verdeca, said last week that its HB4 drought-tolerant soybeans received approval from the U.S. Department of Agriculture. The stock was up 2.2% on volume of of 1.2 million shares ahead of Tuesday's open, but had been up as much as 25.5% earlier in the premarket. The stock had run up 244% over the past two sessions, including a 124.4% rally on volume of 56.7 million shares on Friday and a 53.7% surge on volume of 38.8 million shares on Monday. The stock has now more than doubled year to date through Monday (up 119%), while the S&P 500 has gained 15.0%.

  • MarketWatch

    Arcadia Biosciences rockets on heavy volume for a 2nd straight day

    Shares of Arcadia Biosciences Inc. rocketed higher again Monday, running up 53% on heavy volume after jetting 124% higher the previous session, to pace the Nasdaq exchanges gainers. Trading volume was 25.4 million shares, compared with the full-day average of about 2 million shares, and after turning over 56.7 million shares on Friday. The stock more than doubled on Friday after Verdeca, a joint venture between Arcadia and Bioceres Crop Solutions Corp. said its HB4 drought-tolerant soybeans received approval from the U.S. Department of Agriculture. Arcadia's stock has now gained 15.6% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has lost 10.2% and the S&P 500 has edged up 2.2%. Arcadia's stock was back up toward levels last seen during the February-March rally, which was on the back of the company's announcement of a cannabis-focused business unit.

  • Davis biotech company shares soar following USDA approval
    American City Business Journals

    Davis biotech company shares soar following USDA approval

    Shares in Davis-based Arcadia Biosciences Inc. shot up 124% Friday on news of a USDA approval for drought-tolerant soybeans the company has developed in a joint partnership with Bioceres Crop Solutions Corp.

  • MarketWatch

    Arcadia Biosciences' stock rockets on heavy volume after USDA approval of drought-tolerant soybeans

    Shares of Arcadia Biosciences Inc. rocketed 97.5% on very heavy volume Friday, after Verdeca, a joint venture between Arcadia and Bioceres Crop Solutions Corp. , said it received approval from the U.S. Department of Agriculture to commercialize its HB4 drought-tolerant soybeans. Trading volume in Arcadia's stock was 28.5 million shares, compared with the full-day average of about 127,000 shares. The rally comes after the stock closed at a record low of $1.92 on Monday Aug. 5. Bioceres's stock rose 6% in morning trading. "HB4 is a novel soybean trait that enhances the traditional herbicide tolerance package to provide yield stability across diverse environments," said Verdeca General Manager Martin Mariani Ventura. "Approval of this technology in the United States is a significant step for the successful commercialization of HB4 technology in the global soybean market." Arcadia's stock has still lost 22.7% over the past three months, while Bioceres shares have run 54.5% and the S&P 500 has gained 1.3%.

  • Verdeca Receives USDA Approval of HB4® Drought Tolerant Soybeans
    PR Newswire

    Verdeca Receives USDA Approval of HB4® Drought Tolerant Soybeans

    -- Novel trait stack expected to help growers facing climate and production challenges -- -- HB4 trait now has regulatory approval in more than 80 percent of the global soybean market -- DAVIS, Calif. ...

  • Arcadia Biosciences Announces Joint Venture with Legacy Ventures Hawaii To Grow, Extract and Sell Superior Hemp Products
    PR Newswire

    Arcadia Biosciences Announces Joint Venture with Legacy Ventures Hawaii To Grow, Extract and Sell Superior Hemp Products

    Venture joins Arcadia's extensive genetic expertise and resources with Legacy's proven experience in extraction and distribution. JV creates one vertically integrated supply chain, from seed to sale, to deliver superior hemp-derived CBD products. Partnership leverages Hawaii's unique geographic and climate advantages for growing hemp year-round and provides access to key international markets.

  • Benzinga

    Scoop: Arcadia Biosciences Announces Joint Venture For Hemp Project In Hawaii

    Arcadia Biosciences (NASDAQ: RKDA ) is expected to announce Tuesday a joint venture with Legacy Ventures Hawaii to grow, extract and sell superior hemp products, Benzinga has learned exclusively. The new ...

  • PR Newswire

    /C O R R E C T I O N -- Arcadia Biosciences, Inc./

    In the news release, Arcadia Biosciences Announces Date of Second-Quarter 2019 Financial Results and Business Highlights Conference Call, issued 05-Aug-2019 by Arcadia Biosciences, Inc. over PR Newswire, ...

  • How Should Investors React To Arcadia Biosciences, Inc.'s (NASDAQ:RKDA) CEO Pay?
    Simply Wall St.

    How Should Investors React To Arcadia Biosciences, Inc.'s (NASDAQ:RKDA) CEO Pay?

    Raj Ketkar became the CEO of Arcadia Biosciences, Inc. (NASDAQ:RKDA) in 2016. This analysis aims first to contrast CEO...

  • PR Newswire

    Arcadia Biosciences Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market

    DAVIS, Calif., June 18, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today announced the closing of its previously announced registered direct offering of 1,489,575 shares of its common stock. The offering was priced at-the-market at a purchase price per share of $4.91, for gross proceeds of approximately $7.31 million. Additionally, in a concurrent private placement, Arcadia issued unregistered warrants to purchase up to 1,489,575 shares of common stock, representing 100 percent of the shares of common stock purchased in the registered direct offering.

  • PR Newswire

    Arcadia Biosciences Announces $7.5 Million Registered Direct Offering Priced At-the-Market

    DAVIS, Calif., June 13, 2019 /PRNewswire/ -- Arcadia Biosciences, Inc. (RKDA), a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,489,575 shares of its common stock, at a purchase price per share of $5.035, in a registered direct offering priced at-the-market. Additionally, Arcadia has also agreed to issue to the investors unregistered warrants to purchase up to 1,489,575 shares of common stock. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering.

  • Thomson Reuters StreetEvents

    Edited Transcript of RKDA earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Arcadia Biosciences Inc Earnings Call

  • Arcadia Biosciences (RKDA) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Arcadia Biosciences (RKDA) Reports Q1 Loss, Misses Revenue Estimates

    Arcadia Biosciences (RKDA) delivered earnings and revenue surprises of -103.28% and -60.50%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Arcadia Biosciences: 1Q Earnings Snapshot

    On a per-share basis, the Davis, California-based company said it had a loss of $2.64. Losses, adjusted for non-recurring costs, were $1.24 per share. The agricultural biotechnology trait company posted ...

  • Business Wire

    Arcadia Biosciences Announces First-Quarter 2019 Financial Results and Business Highlights

    Company launches new business unit, Arcadia Specialty Genomics™, to apply its advanced plant breeding and gene editing expertise to cannabis

  • Arcadia Biosciences (RKDA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Arcadia Biosciences (RKDA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Arcadia Biosciences (RKDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire

    Arcadia Biosciences Announces Date of First-Quarter 2019 Financial Results and Business Highlights Conference Call

    Arcadia Biosciences, Inc. , a food ingredient company and proven leader in agricultural innovation, improving the quality and nutritional content of crops, today announced its plan to release its first-quarter 2019 financial and business results after market close on May 8, 2019.

  • Business Wire

    Arcadia Biosciences Welcomes Dr. Randy Shultz as Head of Research and Development

    Arcadia Biosciences, Inc. (RKDA), a food ingredient company and proven leader in agricultural innovation to improve the quality and nutritional content of crops, announced today that Randy Shultz, Ph.D. has joined the company’s leadership team as head of research and development. Shultz has nearly 20 years of experience in plant science and agricultural biotechnology. Shultz was the first key scientific hire at Inari, and played an instrumental role in building a scalable R&D platform and developing a foundational intellectual property estate.

  • Thomson Reuters StreetEvents

    Edited Transcript of RKDA earnings conference call or presentation 27-Mar-19 8:30pm GMT

    Q4 2018 Arcadia Biosciences Inc Earnings Call

  • Associated Press

    Arcadia Biosciences: 4Q Earnings Snapshot

    DAVIS, Calif. (AP) _ Arcadia Biosciences Inc. (RKDA) on Wednesday reported a loss of $646,000 in its fourth quarter. On a per-share basis, the Davis, California-based company said it had a loss of 14 cents.